LINQ is at Drug Discovery 2023 in Liverpool, this October
The scientific and technological advancements in medicine are driving a healthcare revolution globally, with personalisation at the heart. From diagnosis, to drug discovery and treatment, new therapies are going from lab to patient at an ever increasing but never fast enough speed. In order to really harness the power of labs and the impact we can have on society through science, new way of working must be developed and invested in. We believe the best way to unlock this potential – whether it’s speed, scale, quality or consistency – will be through the widespread adoption of end-to-end lab automation.
By robotically and digitally connecting workflows, barriers to innovation can be quickly identified and rectified: lengthy set ups become a thing of the past; machines no longer sit idle; and highly qualified staff aren’t tied to menial tasks and antisocial hours. What’s more, the quality of data is improved and delivered in a way that’s actually useable; consistency, traceability, repeatability is no longer an issue; and responding to changes in instrumentation, demand, and chemistries becomes exhilarating, not feared.
Scientists and engineers from Automata will also be on hand at booth E17 to talk about your opportunities and challenges, and what your lab of the future could look like with an open, integrated automation system like LINQ.
Automating iPSC manufacturing with bit.bio
We’re proud to partner with cell biology experts bit.bio to automate a key aspect of the manufacturing process of their iPSC (induced pluripotent stem cell) derived human cell products.
This partnership will allow bit.bio to streamline the production precision of reprogrammed human cells, turning it into a consistent, standardised process.
We believe this automation will not only free up scientists’ time, reduce human errors and increase batch to batch reliability, but it’s expected to quadruple output at speed.